Drug Profile
Research programme: serotonin 2C receptor agonists - Synaptic Pharmaceuticals/Eli Lilly and Company
Latest Information Update: 20 Aug 2007
Price :
$50
*
At a glance
- Originator Lundbeck Research USA
- Developer Eli Lilly and Company; Lundbeck Research USA
- Class
- Mechanism of Action Serotonin 2C receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 02 Sep 1999 Preclinical development for Obesity in USA (Unknown route)